Business Gujarat Top Stories

Axio Biosolutions launches SureKlot, India’s first complete veterinary wound management solution

The Bengaluru-based homegrown integrated wound care companyexpands their offeringsinto the global animal wound care market expected to touch $1.4 billion by 2024.

Ahmedabad, 5th March 2021:India’s homegrown integrated wound care company, Axio Biosolutions, has announced its expansion into the veterinary wound management space with the launch ofSureKlotrange of products. Thisadvanced wound care range offers India’s first complete veterinary wound management solution to help control bleeding and support quick wound recovery in animals.

Funded by Ratan Tata’s UC RNT, Omidyar Network, Accel and Chiratae Ventures, Axiohadintroduced its latest range on a pilot basis in select hospitals across the country.The company officially launchedthe SureKlot range atJivdaya Charitable Trustin Ahmedabad today. The event, attended by the city’s leading veterinary doctors and veterinary students, was also webcast through Axio’s Facebook Live page.

Leo Mavely, Founder and CEO, Axio Biosolutions said, “We are delighted to bring our Advanced woundcare range for Animals this year. This has been in works for some time and has received great feedback from Surgeons and Veterinary doctors during the pilot. The Veterinary market is often neglected without any medical products to treat common injuries. We are glad to address this by providing world-class products to manage bleeding and infected wounds quickly. We hope to work closely with Vets, Pet parents and our furry friends to constantly bring products that matter to them.”

SureKlot Stop Bleeding Dressing Veterinary Patch
For moderate to severe bleeding wounds

SureKlot Stop Bleeding Dressing Veterinary Gauze
For minor bleeding and wound management

SureKlot Rapid Action Wound Spray Veterinary
For wound cleansing, rinsing, decontamination and moisturising

SureKlot Rapid Action Wound Powder Veterinary
For deep wounds and rapid wound recovery

First-of-its-kindproducts manufactured in Ahmedabad, the SureKlotrange is based on proven technology (made up of 100% Chitosan) that stops uncontrollable bleeding, decontaminates the wound and enhances wound healing. It is sterile, easy to use and can be cut,folded, and stuffed into deep wounds as per the requirement. What’s more, the products ensure painless removal, providing a comfortable experience for the animal.

Dr Shashikant Jadhav, Clinical Director, Jivdaya Charitable Trust stated, “We are proud to be associated with Axio Biosolutions for the launch of SureKlot. It’s heartening to see such top-notch innovation in the veterinary space. At Jivdaya, we continue to see animals injured and in pain every day. Such disruptive products in animal wound care will help us offer better hospital care for the animals in distress and help them recover faster – which, in turn, will help us attend to more animals in need. It gives me hope for a better tomorrow – for animals and humans.”

Dr Kiran Sonaje, Head – R&D,Axio Bisolutions, further noted, “What distinguishes SureKlotproducts is that they aremade of 100% Chitosan, a natural biopolymer derived from shellfish, which helps control bleeding and enhances wound healing. Also, it is non-toxic – which is great because animals have a habit of licking their wounds. I find themparticularly effective in treating bite wounds that are difficult to suture, during surgeries to control bleeding, as well as post-surgeries where therisk of infection is high.”

Sureklot is available in a Patch, Gauze, Powder, and Spray form to suit different types of wounds. It is recommended for emergency trauma and deep cuts, arterial or venous bleeding, surgical/procedural bleeding, bleeding from animal paws and hooves and animal chest and abdominal wounds.

The product range will be available Pan-India through as well as e-commerce platforms like Amazon, Flipkart, 1mg and leading pet retail outlets and online shopping portals for pets.

About Axio Biosolutions
Axio was founded in  2008  by  Leo  Mavely,  a  bioengineer to develop novel biopolymer- platform-based products for wound care. Axio has the distinction of being the first company from India to get USFDA clearance for a hemostat. The vision of Axio is to develop affordable, high-impact medical products that can solve the unmet healthcare needs of emerging markets and is a leading player in chitosan-based medical products.
With a presence in over 28 countries, Axio is today a global name that uses innovative medical technology to create breakthrough products and save people’s lives. Axio has raised $14 Million+ from Ratan Tata’s UC RNT, Omidyar Network, Accel & Chiratae Ventures. Axio’s flagship product Axiostat is regularly used by Indian Armed forces, BSF, NSG, and other para-military forces, as part of their defence kit, during their operations at the border and conflict zones such as North-East. Axio’s customers also include numerous government hospitals and reputed private institutions such as AIIMS, Manipal, Apollo, Breach Candy and Fortis, among others.

In 2019, Axio launched their second line of products- MaxioCel, a ‘first of its kind’ wound care product that provides comfort and accelerates healing for patients suffering from chronic wounds. Earlier this year, MaxioCel received the European CE Mark of approval. With a colossal increase in the number of patients suffering from chronic wounds due to diseases like diabetes, the product holds immense promise to help improve the quality of life of millions.

In 2020, responding to the growing demand for healthcare solutions that align with changing realities and challenges of the pandemic world, Axio Biosolutions made the strategic decision to enter the retail space in India with all its products- wound care and Covid essentials.

Axio has a state-of-the-art manufacturing facility at Gujarat Pharma Techno Park in Ahmedabad. The company is the largest chitosan medical products manufacturer globally. The facility is ISO 13485 certified and GMP approved.,

Leave a Reply

Your email address will not be published. Required fields are marked *